Your session is about to expire
What is Bortezomib
BortezomibThe Generic name of this drug
Treatment SummaryBortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma.[A204083] The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib.[L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib.[A204083]
Bortezomib was first synthesized in 1995.[A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE.[A204146] Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.[A214307]
Velcadeis the brand name
Bortezomib Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Velcade
Bortezomib
2003
29
Approved as Treatment by the FDA
Bortezomib, commonly known as Velcade, is approved by the FDA for 2 uses like Multiple Myeloma and Mantle Cell Lymphoma .Multiple Myeloma
Mantle Cell Lymphoma
When to interrupt dosage
The suggested dosage of Bortezomib is contingent upon the diagnosed condition. The dose will vary, in accordance with the mode of delivery outlined in the table below.Condition
Dosage
Administration
Mantle Cell Lymphoma
, 3.5 mg, 1.0 mg, 2.5 mg, 1.0 mg/mL, 3.0 mg
, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intravenous; Subcutaneous, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Subcutaneous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous
Multiple Myeloma
, 3.5 mg, 1.0 mg, 2.5 mg, 1.0 mg/mL, 3.0 mg
, Intravenous; Subcutaneous, Powder, for solution, Powder, for solution - Intravenous; Subcutaneous, Injection, powder, for solution, Injection, powder, for solution - Intravenous; Subcutaneous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous
Warnings
Bortezomib ContraindicationsCondition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Bortezomib may interact with Pulse Frequency
intrathecal administration
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Bortezomib may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Bortezomib may interact with Pulse Frequency
Common Bortezomib Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Bortezomib is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Bortezomib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Bortezomib is combined with Abetimus.
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Bortezomib.
Acteoside
Major
The risk or severity of adverse effects can be increased when Bortezomib is combined with Acteoside.
Bortezomib Novel Uses: Which Conditions Have a Clinical Trial Featuring Bortezomib?
Currently, there are zero active trials examining the potential of Bortezomib to be used in the treatment of undefined conditions.Condition
Clinical Trials
Trial Phases
Mantle Cell Lymphoma
93 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Multiple Myeloma
11 Actively Recruiting
Phase 1, Phase 2
Bortezomib Reviews: What are patients saying about Bortezomib?
5Patient Review
10/1/20075Patient Review
7/17/20154Patient Review
12/13/2016Patient Q&A Section about bortezomib
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What drug class is bortezomib?
"Bortezomib is a type of medication that helps to kill cancer cells. This medication is known as an antineoplastic agent."
Answered by AI
Is bortezomib a immunotherapy?
"The findings from this study predict that bortezomib has the potential to be a safe and effective immunotherapy drug when used in conjunction with other immune therapies."
Answered by AI
Is bortezomib a chemotherapy drug?
"Vercade (bortezomib) is a targeted chemotherapy that inhibits the proteasome. It is approved by the FDA to treat multiple myeloma and mantle cell lymphoma. Vercade has shown to be effective in many clinical trials."
Answered by AI
What is bortezomib mechanism of action?
"The mechanism of action for Bortezomib is that it inhibits the 26S proteasome, which then prevents the activation of NF-κB. Bortezomib induces apoptosis in cells that are rapidly dividing and are active in synthesizing proteins."
Answered by AI